Copyright
©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Feb 24, 2019; 10(2): 52-61
Published online Feb 24, 2019. doi: 10.5306/wjco.v10.i2.52
Published online Feb 24, 2019. doi: 10.5306/wjco.v10.i2.52
Existing anti-angiogenic therapeutic strategies for patients with metastatic colorectal cancer progressing following first-line bevacizumab-based therapy
Ozkan Kanat, Hulya Ertas, Department of Medical Oncology, Faculty of Medicine, Uludag University, Bursa 16059, Turkey
Author contributions: Kanat O assigned the issue, performed the majority of the writing, and prepared the figures and tables; Ertas H performed extensive literature research on the subject.
Conflict-of-interest statement: There is no conflict of interest associated with any of the senior authors or other coauthors contributed their efforts in this manuscript.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Ozkan Kanat, MD, PhD, Professor, Department of Medical Oncology, Faculty of Medicine, Uludag University, Gorukle, Bursa 16059, Turkey. ozkanat@uludag.edu.tr
Telephone: +90-22-42951321 Fax: +90-22-42951341
Received: September 25, 2018
Peer-review started: September 25, 2018
First decision: November 1, 2018
Revised: November 8, 2018
Accepted: January 5, 2019
Article in press: January 6, 2019
Published online: February 24, 2019
Peer-review started: September 25, 2018
First decision: November 1, 2018
Revised: November 8, 2018
Accepted: January 5, 2019
Article in press: January 6, 2019
Published online: February 24, 2019
Core Tip
Core tıp: Anti-angiogenic treatment is an essential part of the current armamentarium against metastatic colorectal cancer (mCRC). For now, bevacizumab is the only drug licensed for the treatment of chemotherapy-naïve patients with mCRC. However, patients undergoing first-line bevacizumab-based therapy eventually develop disease progression and become candidates for second-line chemotherapy. In this manuscript, we discuss the available anti-angiogenic therapeutic strategies that have been proven to be useful in the treatment of patients with mCRC in whom first-line bevacizumab-based therapy was ineffective.